Entrada Therapeutics has announced that they have dosed their first participant in a Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44 skipping amenable.

Initiation of this Phase 1 clinical trial marks Entrada’s transition into a clinical company, with data anticipated in the second half of 2024.

“The initiation of our Phase 1 trial for ENTR-601-44 is an important step forward in addressing this relentlessly progressive neurodegenerative disease.

Today’s announcement marks Entrada’s transition into a clinical company. As we enter our next phase of growth, Entrada is well-positioned to advance this initial program, as well as our broader Duchenne franchise, and we expect to report data from the Phase 1 trial in the second half of 2024.”

Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics

The primary objective of Entrada’s Phase 1 clinical trial, conducted in the United Kingdom, is to evaluate the safety and tolerability of a single dose of ENTR-601-44 in healthy male volunteers, with a target enrollment of approximately 40 participants. The trial will also evaluate pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.